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A major adverse eﬀect of levodopa therapy is the development of dyskinesia, which aﬀects 30–40% of chronically treated
Parkinsonian patients. We hypothesized that our rehabilitation protocol might allow a reduction in levodopa dosage without
worsening motor performances, thus reducing frequency and severity of dyskinesias. Ten Parkinsonian patients underwent a 4-
week intensive rehabilitation treatment (IRT). Patients were evaluated at baseline, at the end of the rehabilitation treatment and
at 6-month followup. Outcome measures were the Unified Parkinson’s Disease Rating Scale Sections II, III, and IV (UPDRS II,
III, IV) and the Abnormal Involuntary Movement Scale (AIMS). At the end of the IRT, levodopa dosage was significantly reduced
(P = 0.0035), passing from 1016 ± 327 to 777± 333mg/day. All outcome variables improved significantly (P < 0.0005 all) by the
end of IRT. At followup, all variables still maintained better values with respect to admission (P < 0.02 all). In particular AIMS score
improved passing from 11.90± 6.5 at admission to 3.10± 2.3 at discharge and to 4.20± 2.7 at followup. Our results suggest that it
is possible to act on dyskinesias in Parkinsonian patients with properly designed rehabilitation protocols. Intensive rehabilitation
treatment, whose acute beneficial eﬀects are maintained over time, might be considered a valid noninvasive therapeutic support
for Parkinsonian patients suﬀering from diskinesia, allowing a reduction in drugs dosage and related adverse eﬀects.
1. Introduction
A variety of drugs have been developed in the last fifty
years and are currently used to control the disability
related to Parkinson’s disease (PD): levodopa, dopamine-
agonists, monoaminoxidase B inhibitors, catechol-O-meth-
yltransferase inhibitors.
A major limiting factor in levodopa therapy is the devel-
opment of motor complications, in particular dyskinesia,
which aﬀects 30–40% of chronically treated PD patients [1].
Dyskinesias can improve by reducing the dopaminergic
therapy, but it is usually cumbersome to decrease the
levodopa dosage since this reduction elicits a worsening of
motor symptoms: an increased bradykinesia, an increased
“oﬀ time,” a reduction of motor performance, and autonomy
in daily activities.
In the last decade, a considerable number of studies have
shown that exercise is eﬀective in improving gait, balance,
freezing, and motor performance in PD. In particular, recent
studies on animals allow hypothesizing a direct action
of physical activity on the mechanisms responsible for
dyskinesias [2, 3].
In this study we present preliminary data on the eﬀec-
tiveness of intensive rehabilitation treatment (IRT) in PD
patients with dyskinesias and on the persistence over time of
its beneficial eﬀects.
2. Methods
2.1. Study Population. Patients were screened from among
those consecutively admitted to the movement disorder
ambulatories of the Rehabilitation Institute of Montescano.
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Eligibility criteria for patients were (a) diagnosis of “clinically
probable” idiopathic Parkinson’s disease according to Gelb
et al. [4], (b) development of dyskinesias in the last 3
years and a history of several failed attempts to improve
dyskinesia by reducing or modifying drug dosage, (c) ability
to walk without any physical assistance, (d) no cognitive
impairment (mini-mental state examination score ≥26),
(e) no comorbidity unrelated to Parkinson’s disease, (f)
no vestibular/visual dysfunction limiting locomotion or
balance, and (h) antiparkinsonian medications stable for >4
weeks.
Ten eligible patients were invited to be admitted to the
Rehabilitation Institute of Montescano for a 4-week intensive
rehabilitation treatment.
Patients were examined by the same neurologist expert
in movement disorders, in the morning, one hour after they
had taken the first dose of levodopa, at baseline, at the end of
the rehabilitation treatment, and at 6-month followup. The
neurologist was blinded with respect to the study design for
the entire period.
The outcomemeasures used were the Unified Parkinson’s
Disease Rating Scale Sections II, III, and IV (UPDRS II,
III, IV) [5] and the Abnormal Involuntary Movement Scale
(AIMS) [6].
Patients were treated with diﬀerent drugs (levodopa, I-
COMT, I-MAOB, or dopamine agonist), and we evaluated
the drug dosage as levodopa equivalent (mg/day).
The study was approved by the local ethics committee,
and all subjects gave their informed written consent before
participation.
2.2. Intervention. IRT consisted of a 4-week cycle of physio-
therapy that entailed three daily sessions (two, not consec-
utive, in the morning and one in the afternoon), 5 days a
week. The global duration of each session, including recovery
periods, was about one hour. The first session comprised car-
diovascular warm-up activities, relaxation exercises, muscle-
stretching exercises (scapular muscle group, hip flexor,
hamstring and gastrocnemius muscles), exercises to improve
the range of motion of spinal, pelvic, and scapular joints,
exercises to improve the functionality of the abdominal
muscles, and postural changes in the supine position.
The second session comprised exercises to improve
balance and gait using a stabilometric platform with a visual
cue (patients were asked to follow a circular pathway on the
screen by using a cursor sensitive to their feet movements
on the platform) and treadmill plus (treadmill training with
both a visual and an auditory cue) [7]. The last session
was a session of occupational therapy aimed at improving
autonomy in daily living activities: transferring from sitting
position to standing position, rolling from supine position
to sitting position and from sitting to supine, dressing, use of
tools, and exercises to improve hand functionality and skills
(e.g., using screws and bolts). Moreover, patients spent 20
minutes every day in front of a mirror in order to control
involuntary and exaggerated movements.
Table 1: Outcome variables at admission, at discharge after a 4-
week intensive rehabilitation treatment, and at 6-month followup.
Variable Admission Discharge
6-month
followup
UPDRS II 14.30± 4.7 9.40± 5.1 9.40± 3.0
UPDRS III 20.00± 4.9 14.10± 4.3 11.60± 4.1
UPDRS IV 7.50± 3.7 1.70± 1.6 2.60± 2.1
AIMS 11.90± 6.5 3.10± 2.3 4.20± 2.7
Levodopa equivalent
1016 ± 327 777 ± 333 777 ± 333
(mg/day)
UPDRS: Unified Parkinson’s Disease Rating Scale (Sections II, III, and IV).
AIMS: Abnormal Involuntary Movement Scale.
During the follow-up period, patients were invited to
continue some simple exercises learnt during hospitalization
period.
2.3. Statistical Analysis. Descriptive statistics are given as
mean ± SD. The Shapiro-Wilk statistic was used to test the
normality of the distribution of all variables.
The eﬀect of treatment on each outcome variable and the
persistence over the 6-month follow-up period were assessed
by repeated measurements analysis of variance with three
repeated measurements: admission, discharge, and 6-month
followup. Pairwise comparisons (discharge versus admission
and 6-month followup versus admission) were carried out
by contrast analysis in repeated measurements analysis
of variance. A P value <0.05 was considered statistically
significant. All analyses were carried out using the SAS/STAT
statistical package, release 9.2 (SAS Institute Inc., Cary, NC,
USA).
3. Results
All 10 patients (aged 70 ± 8 years, duration of the disease
11.4±2.4 years) completed the intensive rehabilitation treat-
ment and the 6-month follow-up control. The characteristics
of patients at admission, discharge and at the follow-up time
are reported in Table 1.
At the end of IRT, levodopa-equivalent dosage was sig-
nificantly reduced (P = 0.0035), passing from 1016± 327 to
777 ± 333mg/day. At follow-up the levodopa-equivalent
dosage was unchanged.
All outcome variables improved significantly by the end
of the rehabilitation treatment (P = 0.0003, P < 0.0001,
P < 0.0001 and P = 0.0005 for UPDRS II, UPDRS III,
UPDRS IV and AIMS, resp.). At followup, all variables still
maintained better values with respect to admission (P =
0.0176, P < 0.0001, P < 0.0001 and P = 0.0026, resp.).
4. Conclusion
In this study we investigated the eﬃcacy of IRT in PD
patients with dyskinesias and the persistence over time
of the beneficial eﬀects of this treatment. We found a
statistically and clinically significant improvement in all
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outcome variables after the 4-week rehabilitation period,
which was largely preserved even after a 6-month period.
The improvement in UPDRS II and III observed in
this study is in accordance with our preview studies, in
which we demonstrated that IRT acts slowing the disease
progression in Parkinsonian patients in a very long followup
[8]. The patients continued to perform the recommended
exercises during the follow-up period and this may explain
the persistence of the beneficial eﬀects obtained during
hospitalization. Moreover, the simple reduction of intensity
and duration of dyskinesias during the day leads the patients
to improve their motor performance and autonomy during
activity of daily life.
Our results suggest that it is possible to act on dyskinesias
in Parkinsonian patients with an IRT. Several preclinical
investigations carried out in animal models of PD have
demonstrated that an overload of redundant motor informa-
tion is stored in the basal gangliamotor circuits of dopamine-
denervated animals.
In particular, the striatum receives the most important
glutamatergic innervation, is the site of interaction gluta-
mate/dopamine, is the source of the inhibitory outputs, and
is involved in the generation ofmotor fluctuation linked to L-
dopa treatment [2]. In animal models, after denervation, the
striatal plasticity is lost, but the chronic L-dopa treatment is
able to restore the long term potentiation (LTP) of synaptic
transmission [9, 10].
The reversal of synaptic strength from the potentiated
state to pre-LTP levels is named depotentiation, and this pro-
cess represents the synaptic process of erasing unnecessary
motor information. In Parkinsonian animal models treated
with L-dopa which show dyskinesias movement, the synaptic
depotentiation is lost [2]. The inability of corticostriatal
synapses to depotentiate might represent the cellular basis of
dyskinesias.
The execution of movements plays a fundamental role
in determining the outcome of subsequent motor responses
elicited by dopamine receptor stimulation [11]. Exaggerated
movements in response to a stimulation of dopaminergic
receptors, such as those occurring during dyskinesia, might
consequently convey erroneous information to the motor
striate circuits. Therefore, when concomitant, competing
correct movements are performed (as during rehabilitation
treatment), the manifestation of abnormal dyskinetic move-
ments may be attenuated.
This study, therefore, suggests the possibility that the
competition between a correct motor behaviour and an
abnormal motor response may depend on the balance
between the trace memory of the two.
Another possible explanation may be related to a neu-
rorestorative strategy. The eﬀects of intensive exercise in
promoting cell proliferation and neuronal diﬀerentiation in
animal models are reported in a large cohort of studies.
In animals with cerebral lesions produced by 6-
hydroxydopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), the intensive use of a treadmill
or running wheels led to improvement in motor perfor-
mance as compared to animals that did not use these devices.
Both in unilateral and bilateral models of PD, intensive
treadmill exercise produced improvement in motor symp-
toms, which was related to a reduction in the neurochemical
deficit: preservation of both tyrosine hydroxylase-positive
fibres in the striatum and substantia nigra, as well as of
vesicular monoamine transporter and dopamine transporter
levels [12–17]. Increased dopamine availability, especially
within the dorsolateral striatum, has been found in an
MPTP mice model after intensive exercise with a motorized
treadmill [18]. Overall, these findings show that intensive
exercise exerts beneficial eﬀects on dopamine transmission
in parkinsonian mice models.
These neuroplastic eﬀects of intensive exercise are prob-
ably related to increased expression of a variety of neu-
rotrophic factors. In particular, brain-derived neurotrophic
factor (BDNF) and glia-derived neurotrophic factor (GDNF)
are the most likely growth factors involved in this process.
BDNF is a key component of a number of aspects of neu-
roplasticity: neurogenesis, synaptogenesis, and cell survival
[19, 20], while GDNF has been shown to promote the
survival and diﬀerentiation of dopamine neurons and to
maintain the survival of adult catecholaminergic neurons
in mice [21, 22]. Tajiri et al. [17] have recently shown that
rat models of PD performing intensive treadmill exercise
experience upregulation of BDNF and GDNF in the striatum
in comparison to rats that do not exercise. These findings are
consistent with the findings of another study by Lau et al.
[23], who showed that intensive treadmill exercise raises the
level of endogenous BDNF and GDNF in the substantia nigra
and striatum.
In conclusion, our findings suggest that properly
designed intensive multidisciplinary rehabilitation treatment
using treadmill should be considered as a valid noninvasive
therapeutic support for patients who show dyskinesias.
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